[Marked efficacy of multimodality therapy for ureteral cancer producing granulocyte colony-stmimulating factor]

Nihon Hinyokika Gakkai Zasshi. 2014 Apr;105(2):43-6. doi: 10.5980/jpnjurol.105.43.
[Article in Japanese]

Abstract

A 69-year-old man was admitted with the chief complaint of macroscopic hematuria. Computerized tomography (CT) and ureteroscopy showed right ureter cancer. Right nephroureterectomy and partial cystectomy were performed. Histological examination revealed urothelial carcinoma of ureter (Grade3, pT3, INFbeta, ly1). The patient underwent two courses of adjuvant chemotherapy with gemcitabine and cisplatin. Three months later, abdominal CT showed a mass in his right obturatorius area. The patient's white blood cell count was 34,140 cells/microl. Additionally serum analysis revealed high value of granulocyte colony stimulating factor (G-CSF), 596 pg/ml with no obvious focus. After being diagnosed with recurrent ureteral cancer producing G-CSF, the patient underwent secondary chemotherapy with gemcitabine and docetaxel. After three courses of chemotherapy, CT revealed a marked decrease in tumor size, and the value of G-CSF declined at 31 pg/nl. Subsequently, radiotherapy (60 Gy) was administered. The patient has been alive for 16 months.

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Carcinoma / metabolism
  • Carcinoma / therapy*
  • Combined Modality Therapy
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Docetaxel
  • Gemcitabine
  • Granulocyte Colony-Stimulating Factor / biosynthesis*
  • Humans
  • Male
  • Taxoids / administration & dosage
  • Ureteral Neoplasms / metabolism
  • Ureteral Neoplasms / therapy*

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Taxoids
  • Deoxycytidine
  • Granulocyte Colony-Stimulating Factor
  • Docetaxel
  • Gemcitabine